| Code | CSB-RA004910MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to BION-1402, targeting CD27, a member of the tumor necrosis factor receptor superfamily. CD27 functions as a critical costimulatory molecule expressed on T cells, B cells, and natural killer cells, playing an essential role in regulating immune cell activation, differentiation, and survival. Upon binding to its ligand CD70, CD27 enhances T cell priming, promotes memory T cell formation, and supports B cell maturation and antibody production. Dysregulation of the CD27-CD70 pathway has been implicated in various hematological malignancies, autoimmune disorders, and viral infections, making CD27 an important target for immunological research.
BION-1402 is an investigational agonistic antibody designed to stimulate CD27 signaling and enhance antitumor immune responses, particularly in oncology settings. This biosimilar antibody provides researchers with a valuable tool for studying CD27-mediated immune modulation, investigating T cell and B cell biology, and exploring therapeutic mechanisms relevant to cancer immunotherapy and immune-related diseases.
There are currently no reviews for this product.